A multicenter phase II study evaluating the efficacy and tolerability of vemurafenib in combination with Pegylated Interferon and Interleukin-2 in patients with BRAF-mutated metastatic melanoma

To evaluate 6 month progression free-survival (PFS) rate of vemurafenib in combination with interleukin-2 (IL-2) and pegylated interferon (IFN) as first line treatment in patients with BRAF-mutated metastatic melanoma